{"id":"clonixin","rwe":[],"tags":[{"label":"clonixin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Dihydroorotate dehydrogenase (quinone), mitochondrial","category":"target"},{"label":"DHODH","category":"gene"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"chlonixin","offLabel":[],"synonyms":["clonixin","chlonixin","clonixic acid","clonixine","clonixin lysinate"],"timeline":[],"aiSummary":"Chlonixin, also known as CLONIXIN, is a small molecule drug that targets dihydroorotate dehydrogenase (quinone), a mitochondrial enzyme. It belongs to the clonixin drug class and is used to treat certain conditions. However, its commercial status and approved indications are unknown. Further research is needed to determine its safety profile and potential side effects. As a result, it is not currently available on the market.","approvals":[],"brandName":"Chlonixin","ecosystem":[],"mechanism":{"target":"Dihydroorotate dehydrogenase (quinone), mitochondrial","targets":[{"gene":"DHODH","source":"DrugCentral","target":"Dihydroorotate dehydrogenase (quinone), mitochondrial","protein":"Dihydroorotate dehydrogenase (quinone), mitochondrial"}],"modality":"Small Molecule","drugClass":"clonixin","explanation":"Think of it like a traffic cop: dihydroorotate dehydrogenase helps control the flow of building blocks for DNA and RNA. Chlonixin acts like a roadblock, preventing this enzyme from doing its job. This can help slow down the growth of cells, which can be beneficial in treating certain conditions.","oneSentence":"Chlonixin works by inhibiting the enzyme dihydroorotate dehydrogenase, which is involved in the production of pyrimidine nucleotides.","technicalDetail":"Chlonixin specifically inhibits dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme that catalyzes the conversion of dihydroorotate to orotate in the pyrimidine biosynthesis pathway."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/705","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CLONIXIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLONIXIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:12:02.803493","biosimilars":[],"competitors":[{"drugName":"atovaquone","drugSlug":"atovaquone","fdaApproval":"1992-11-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"ciclosporin","drugSlug":"ciclosporin","fdaApproval":"1983-11-14","relationship":"same-target"},{"drugName":"flunixin","drugSlug":"flunixin","fdaApproval":"","relationship":"same-target"},{"drugName":"leflunomide","drugSlug":"leflunomide","fdaApproval":"1998-09-10","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"teriflunomide","drugSlug":"teriflunomide","fdaApproval":"2012-09-12","patentExpiry":"Sep 14, 2030","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"clonixin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"atovaquone","brandName":"atovaquone","genericName":"atovaquone","approvalYear":"1992","relationship":"same-target"},{"drugId":"ciclosporin","brandName":"ciclosporin","genericName":"ciclosporin","approvalYear":"1983","relationship":"same-target"},{"drugId":"flunixin","brandName":"flunixin","genericName":"flunixin","approvalYear":"","relationship":"same-target"},{"drugId":"leflunomide","brandName":"leflunomide","genericName":"leflunomide","approvalYear":"1998","relationship":"same-target"},{"drugId":"teriflunomide","brandName":"teriflunomide","genericName":"teriflunomide","approvalYear":"2012","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01421433","phase":"PHASE3","title":"A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol","status":"UNKNOWN","sponsor":"Farmoquimica S.A.","startDate":"2012-05","conditions":["Low Back Pain"],"enrollment":160,"completionDate":"2013-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000167333","NDDF":"004344","UNII":"V7DXN0M42R","CHEBI":"CHEBI:76200","INN_ID":"2718","RXNORM":"2601","UMLSCUI":"C0009018","ChEMBL_ID":"CHEMBL1332971","KEGG_DRUG":"D03555","DRUGBANK_ID":"DB09218","PDB_CHEM_ID":"6J3","PUBCHEM_CID":"28718","MESH_DESCRIPTOR_UI":"D003002"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":44,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}